Triclabendazole is a benzimidazole anthelmintic. It eliminates both immature and adult flukes in a sheep model of F. hepatica infection when administered at a dose of 10 mg/kg. Triclabendazole (5 μM) also protects against glucose- or α-synuclein-induced apoptosis in S. cerevisiae via inhibition of adenylyl cyclase in the Ras-adenylyl cyclase-protein kinase A (PKA) nutrient sensing pathway.
An anthelmintic (fasciola).
Triclabendazole is classified under the category of ‘Anthelmintic flukicide for veterinary use.
ChEBI: 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole is an aromatic ether.
Synthesis of Triclabendazole
Triclabendazole (20-100 mg/kg, Intraperitoneal injection, twice a week for 2 weeks) has anti-tumor effect in the xenograft MDA-MB-231 cells model nude mice[1].
Caspase-8; Caspase-9; Caspase 3; Leishmania; Bcl-2; Bax; PARP
[1] Patent: CN106632067, 2017, A. Location in patent: Paragraph 0016; 0020
